Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Galderma R&D
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female who is at least 18 years of age.
Clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea.
CEA (clinician's erythema assessment) score greater than or equal to 3 at Screening and on Treatment visit at baseline.
PSA (patient self assessment) score of greater than or equal to 3 at Screening and on Treatment visit at baseline.
Presence of 2 or fewer inflammatory facial lesions.
You may not be if
History of Raynaud's Syndrome, glaucoma, orthostatic hypotension, thromboangiitis obliterans, cerebral or coronary insufficiency, or depression.
History of refractive surgery such as photorefractive keratectomy.
The subject is being treated with monoamine oxidase (MAO) inhibitor, anti-depressants, barbiturates, opiates, sedatives, systemic anesthetics, alpha-agonists, beta blockers, antihypertensive agents, cardiac glycosides, or systemic anticoagulants.
The subject is currently enrolled in an investigational drug or device study or participated in such a study in the past 3 months prior to enrollment and is still in the exclusion period on the day of the Treatment visit.
Clareo Health | Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
